RE:RE:RE:RE:The issue of the safe use of higher doses of vaccinia virus July 21, 2023 - Turnstone Biologics closes $80 million IPO.
The San Diego-based company has already set how it plans to use the money to fund phase 1 work on its lead asset TIDAL-01 for breast and colorectal cancers as well as move another tumor-infiltrating lymphocyte into the clinic and run combination trials with viral immunotherapies.
In July 2022 Takeda walked away from the vaccinia virus cancer prospect it picked up in a $120 million deal from Turnstone Biologics in 2019 due to the explicitly referred to "safety signal" of the pathologic vaccina virus.
https://www.fiercebiotech.com/biotech/turnstone-turns-fortunes-around-80m-ipo-haul